Should You Buy Alexandria Real Estate Equities Inc (ARE) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
ARE is not a good buy right now for a beginner long-term investor with $50k–$100k who wants to act immediately. The stock is near short-term resistance while fundamentals and Wall Street expectations have recently deteriorated (large revenue drop, major net loss, and multiple price-target cuts after the investor-day reset). There are some balance-sheet optimization positives (asset sales, debt tender), but the life-science/lab real estate supply-demand backdrop is expected to stay challenging for years, which limits near-to-medium-term upside and increases the chance of further downside from here.
Technical Analysis
Price/levels: Pre-market ~$57.83, sitting slightly above the pivot (56.956) and below first resistance (R1 59.305). This is a "middle of the range" spot, not a clear value entry, and it’s close enough to resistance that upside may be capped near-term.
Momentum: MACD histogram is positive (0.44) but positively contracting, implying bullish momentum is fading rather than accelerating. RSI(6) ~61.6 is neutral-to-slightly-warm (not oversold), so the chart is not signaling a bargain entry.
Trend structure: Converging moving averages suggests indecision/transition rather than a strong trend.
Quant-style short horizon read: Pattern-based stats provided imply slightly negative drift over the next week/month (-1.2% / -3.33%), consistent with a weak-to-choppy setup.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Analyst Ratings and Price Target Trends
Recent trend: Broadly negative revisions into late 2025 and early 2026. Multiple firms cut price targets after the investor day, reflecting reduced earnings/FFO confidence and a longer recovery timeline for lab demand.
- Notable recent calls: Morgan Stanley initiated at Equal Weight with a $55 PT (around/below current levels). Several firms maintained Neutral/Hold while cutting PTs into the mid-$40s to low-$50s (e.g., $45, $46, $47, $48, $50, $52). A few Outperform ratings remain, but even they lowered targets (e.g., $60, $64, $67).
Wall Street pros view: Strong assets/portfolio quality, balance-sheet actions (dispositions, potential de-leveraging), and stabilization potential if/when life-science demand recovers.
Wall Street cons view: Multi-year oversupply/vacancy headwinds, weaker biotech funding trends, reduced negotiating leverage for landlords, guidance resets, and limited earnings visibility—leading to capped upside and higher downside risk near-term.
Trading behavior checks: Hedge funds and insiders are Neutral (no significant recent trends). Congress trading: no recent data available. Politicians/influential figures: none provided in the dataset.
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 54.610
Current: 54.610
